Sunitinib is a generic form of brand name Suninat 50mg and the drug is a cancer medicine whichinhibits the growth and spread of cancer cells in the body.
Suninat 50mg is a type of targeted therapy and is a receptor protein-tyrosine kinase inhibitor. It prevents the actions of vascular endothelial growth factor (VEGF) and is an angiogenesis inhibitor.
Suninat 50mg is a prescription drugs which is used under the guidance of medical practioners
Suninat 50mg is used for the treatment of following conditions :
• Gastrointestinal stromal tumor
• Advanced pancreatic neuroendocrine tumor
• Advanced renal cell cancer.
Sunitinib is performing to stop tumor cell development in several ways. Sunitinib aims several enzymes on blood vessel cells and cancer cells. Various of these targets are thought to be included in angiogenesis (making of blood vessels).
High plasma concentration of sunitinib is between 6 and 12 hours and the bioavailability of sunitinib has no effect on food.
Human plasma protein binding was 95 % and 90 % respectively.
Primarily metabolized by cytochrome P450 enzyme, CYP3A4
The drug sunitinib is eliminated primarily through feces 61% and renal excretion is 16% of administrated dose. Sunitinib half-life is 40 – 60 hours Primary active metabolite half-life was 80 – 110 hours
DOSAGE AND ADMINISTRATION
The recommended dosage for following condition as follows :
Gastrointestinal Stromal Tumor :
Dose after disease progression on or intolerance to imatinib mesylate
The recommended dose is 50 mg PO qDay for 4 weeks, followed by 2 weeks drug-free, repeat cycle
Renal Cell Carcinoma :
The recommended dose is 50 mg PO qDay for 4 weeks, followed by2 weeks drug-free, repeat cycle
Adjuvant treatment of RCC :
• used for the adjuvant therapy of adult patients at high risk of recurrent RCC following nephrectomy
• The recommended dose is 50 mg PO qDay for 4 weeks, followed by2 weeks drug-free, repeat cycle for a maximum of nine 6-week cycles totally
Pancreatic Neuroendocrine Tumor :
Required for progressive, well-differentiated pancreatic neuroendocrine tumor (pNET) in patients with unresectable locally advanced or metastatic disease
The recommended dose is 37.5 mg PO qDay continuously without a scheduled off-treatment period
Common side effects :
Signs of allergic reactions:
hives, breathing difficulty, sore throat, skin pain, red or purple skin rash
upper stomach pain, itching, tried feeling, decreased appetite, dark urine, jaundice.
Serious side effects :
Swelling in ankles or feet
Fast heart beats
Shortness of breath
Signs of tumor cell breakdown :
muscle cramps, tiredness, decreased urination, slow heart rate.
severe tiredness, depression, rapid heart rate, , feeling nervous, sweating, nausea, vomiting, diarrhea, loss of hair, weight changes, irregular menstrual periods.
Suninat 50mg treatment will causes severe hepatotoxicity involving liver failure; check liver function tests before starting treatment.
Haemorrhagic events involving tumor-related haemorrhageresulted; test the serial complete blood counts and physical examinations
Adrenal haemorrhageoccurred in animal studies; check the adrenal function in case of stress such as surgery, trauma or severe infection
Control urine protein; interfere with treatment for 24-hr urine protein ≥3 g; stop for repeat episodes of protein ≥3 g despite dose reductions or nephrotic syndrome
Hypothyroidism occurred; check the baseline thyroid function in patients with hypothyroidism or hyperthyroidism and treat per standard medical practice prior to initiating therapy
Impaired wound healing resulted; temporary interferewithtreatment recommended if go through major surgical procedures